インサイダー取引

Open market or private purchase of non-derivative or derivative security

• F2 The conversion of the Notes will be made based on a conversion rate of $1.21 per share.
• F1 On November 9, 2026, the Issuer entered into a note purchase agreement (the Purchase Agreement) with certain investors, including DAFNA Capital Management, LLC (DAFNA), on behalf of funds of which it is the investment manager and general partner, for the purchase of convertible promissory notes (the Notes). DAFNA acquired Notes under the Purchase Agreement in the aggregate principal amount, and for a total purchase price, of $2,000,000. The Notes have a maturity date of November 9, 2029 and bear interest at a rate of 10% per annum, which may be paid in cash or in kind be adding the amount of interest to the principal balance.
• F3 The Notes and accrued interest are convertible into shares of the Issuer's Common Stock at the election of the holders at any time prior to the maturity date or the consummation of a merger, sale, consolidation or reorganization of the Issuer, subject to a 19.9% beneficial ownership blocker. If the Notes cannot be fully converted due to the NYSE American exchange cap, then no portion of the Notes will convert into the Issuer's Common Stock until the Issuer has obtained stockholder approval to the waiver of the exchange cap.
• F4 Held by funds of which DAFNA is the investment manager and general partner. Dr. Fischel is the Chief Executive Officer, of DAFNA Capital Management, LLC.

Open market or private purchase of non-derivative or derivative security

• F2 The conversion of the Notes will be made based on a conversion rate of $1.21 per share.
• F1 On November 9, 2026, the Issuer entered into a note purchase agreement (the Purchase Agreement) with certain investors, including DAFNA Capital Management, LLC (DAFNA), on behalf of DAFNA LifeScience, L.P. and DAFNA LifeScience Select, L.P. (the Funds), for the purchase of convertible promissory notes (the Notes). DAFNA acquired Notes under the Purchase Agreement in the aggregate principal amount, and for a total purchase price, of $2,000,000. The Notes have a maturity date of November 9, 2029 and bear interest at a rate of 10% per annum, which may be paid in cash or in kind be adding the amount of interest to the principal balance.
• F3 The Notes and accrued interest are convertible into shares of the Issuer's Common Stock at the election of the holders at any time prior to the maturity date or the consummation of a merger, sale, consolidation or reorganization of the Issuer, subject to a 19.9% beneficial ownership blocker. If the Notes cannot be fully converted due to the NYSE American exchange cap, then no portion of the Notes will convert into the Issuer's Common Stock until the Issuer has obtained stockholder approval to the waiver of the exchange cap.
• F4 The reported securities are directly owned by the Funds. DAFNA may be deemed to beneficially own the reported securities as the investment manager and general partner of the Funds. The reported securities may also be deemed beneficially owned by Dr. Fariba Ghodsian as the Chief Investment Officer of DAFNA. DAFNA and Dr. Ghodsian disclaim beneficial ownership of the reported securities except to the extent of its and her respective pecuniary interest therein, if any. This report shall not be deemed an admission that DAFNA or Dr. Ghodsian is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Open market or private purchase of non-derivative or derivative security